by Clinical Neuropsychologist Online | Friday, August 2, 2024 | Dementia
Abstract INTRODUCTION Triggering receptor expressed on myeloid cells 2 (TREM2) agonists are being clinically evaluated as disease-modifying therapeutics for Alzheimer’s disease. Clinically translatable pharmacodynamic (PD) biomarkers are needed to confirm drug...
by Clinical Neuropsychologist Online | Friday, August 2, 2024 | Neuroscience
Nature Neuroscience, Published online: 02 August 2024; doi:10.1038/s41593-024-01724-1Studying GnRH neuroendocrine cells in the mouse olfactory bulb (GnRHOB neurons), Decoster et al. show that these cells respond to female odors and their activation regulates males’...
by Clinical Neuropsychologist Online | Thursday, August 1, 2024 | Dementia
Abstract INTRODUCTION We disclosed amyloid positron emission tomography (PET) results in individuals with subjective cognitive decline (SCD) and studied patient experiences and outcomes over a 6-month period. METHODS Fifty-seven participants from the Subjective...
by Clinical Neuropsychologist Online | Thursday, August 1, 2024 | Dementia
Abstract INTRODUCTION In Down syndrome (DS), white matter hyperintensities (WMHs) are highly prevalent, yet their topography and association with sociodemographic data and Alzheimer’s disease (AD) biomarkers remain largely unexplored. METHODS In 261 DS adults...
by Clinical Neuropsychologist Online | Thursday, August 1, 2024 | Neuro Podcasts
This episode is a conversation with Dr. Catherine Price about perioperative cognitive decline (including delirium), particularly in older adults. Various topics are covered, including the frequency of cognitive problems post-surgery, predisposing and precipitating...
